Yahoo Finance

Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg ...

HAMPTON, N.J., Nov. 05, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data from the Company’s Phase 1b study of barzolvolimab in prurigo nodularis (PN).
Yahoo Finance

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

HAMPTON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 2 subcutaneous study of ...
Business Wire

Mayo Clinic and PN Medical Publish Study that Shows How to Reduce Stress and Anxiety

An 18% reduction in stress was one of the most significant outcomes. ORLANDO, Fla.--(BUSINESS WIRE)--Mayo Clinic released the results of a clinical trial demonstrating the positive outcomes of a ...
Nasdaq

Protagonist (PTGX) Begins Dosing in Phase I Study With PN-235

Protagonist Therapeutics, Inc. PTGX announced that it has dosed the first patient in a phase I study, evaluating its oral interleukin-23 receptor (IL-23R) antagonist peptide – PN-235 (also known as ...